General Information


We are a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. We use our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTACs, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a new therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines.

Employees: 69
Founded: 2013
Contact Information
Address 5 Science Park, 395 Winchester Ave., New Haven, CT 06511, US
Phone Number (203) 535-1456
Web Address
View Prospectus: Arvinas
Financial Information
Market Cap $514.5mil
Revenues $11.7 mil (last 12 months)
Net Income $-97.8 mil (last 12 months)
IPO Profile
Symbol ARVN
Exchange NASDAQ
Shares (millions): 7.5
Price range $16.00 - $16.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Goldman Sachs/ Citigroup/ Piper Jaffray
CO-Managers -
Expected To Trade: 9/27/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change